La Distia Nora Rina, Putera Ikhwanuliman, Khalisha Dhiya Farah, Septiana Indah, Ridwan Asri Salima, Sitompul Ratna
Department of Ophthalmology, Faculty of Medicine, Universitas Indonesia - Cipto Mangunkusumo Kirana Eye Hospital, Jakarta, Indonesia.
Department of Immunology, Erasmus Medical Center, Rotterdam, Netherlands.
BMJ Open Ophthalmol. 2020 Sep 6;5(1):e000563. doi: 10.1136/bmjophth-2020-000563. eCollection 2020.
To review and critically appraise the ocular manifestation and the presence of SARS-CoV-2 through PCR positivity from ocular samples in COVID-19-related patients. Moreover, to evaluate the time and severity association of ocular manifestation to systemic disease of COVID-19.
A systematic literature search from PubMed, ScienceDirect and Google Scholar databases was performed using standardised Preferred Reporting Items for Systematic Reviews and Meta-Analyses guideline. Selected keywords were related to COVID-19, ocular manifestation and PCR testing of SARS-CoV-2. Studies were assessed for their validity, and the data were extracted by two independent reviewers. Observational, case series and case report studies were included if they met the selection criteria. Meta-analysis was performed to estimate the pooled prevalence of ocular manifestations and PCR positivity from tears.
Thirty-one articles were qualitatively reviewed, and 14 studies were included in the meta-analysis. The pooled prevalence of ocular manifestation among COVID-19-related patients was 0.05 (95% CI 0.02% to 0.08). The overall PCR from tears samples positivity rate from COVID-19-related patients presenting with ocular manifestation was 0.38 (95% CI 0.14% to 0.65). Ocular manifestation could precede systemic manifestation in about 0.28 (95% CI 0.05% to 0.58) of COVID-19-related patients with ocular manifestations. Besides, ocular manifestation was not associated with a severe form of COVID-19.
Although the overall number of ocular manifestation and SARS-CoV-2 PCR positivity rate from ocular samples was very low, around a quarter of COVID-19-related patients with ocular manifestation presented their ocular manifestation earlier than the systemic manifestation regardless of the severity. Interestingly, SARS-CoV-2 PCR was positive from one-third of ocular samples, which could potentially be the source of infection to the respiratory tract and the environment, although the infectivity is yet to be determined.
回顾并批判性评估新型冠状病毒肺炎(COVID-19)相关患者眼部表现以及通过眼部样本PCR检测呈阳性来确定严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的存在情况。此外,评估眼部表现与COVID-19全身性疾病的时间及严重程度关联。
依据系统评价和Meta分析的首选报告项目(PRISMA)指南,在PubMed、ScienceDirect和谷歌学术数据库中进行系统文献检索。选定的关键词与COVID-19、眼部表现以及SARS-CoV-2的PCR检测相关。对研究进行有效性评估,数据由两名独立评审员提取。符合入选标准的观察性研究、病例系列研究和病例报告研究纳入分析。进行Meta分析以估计眼部表现的合并患病率以及泪液样本中PCR阳性率。
对31篇文章进行定性综述,14项研究纳入Meta分析。COVID-19相关患者中眼部表现的合并患病率为0.05(95%置信区间0.02%至0.08)。出现眼部表现的COVID-19相关患者泪液样本的总体PCR阳性率为0.38(95%置信区间0.14%至0.65)。在约0.28(95%置信区间0.05%至0.58)有眼部表现的COVID-19相关患者中,眼部表现可能先于全身表现出现。此外,眼部表现与严重型COVID-19无关。
尽管眼部表现的总体数量以及眼部样本的SARS-CoV-2 PCR阳性率非常低,但约四分之一有眼部表现的COVID-19相关患者,无论病情严重程度如何,其眼部表现均早于全身表现。有趣的是,三分之一的眼部样本SARS-CoV-2 PCR呈阳性,尽管其传染性尚待确定,但这可能是呼吸道和环境感染源。